Finerenone in IgA nephropathy: real-world 12-month propensity-matched cohort demonstrating proteinuria reduction, eGFR preservation, and safety profile

Objective To evaluate the efficacy and safety of finerenone in patients with IgA nephropathy (IgAN).Methods This retrospective study included 105 patients with IgAN (35 in the finerenone group, 70 in the control group) from January 2022 to February 2025. The finerenone group received conventional th...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Wei Zhang, Jing-ting Yu, Bo Lin, Xiaogang Shen, Maosheng Chen, Yi-dong Zhou, Yu-jia Zhang, Cheng-cong Zhuo, Zhi-liang Jiang, Bin Zhu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2026-12-01
coleção:	Renal Failure
Assuntos:	IgA nephropathy finerenone non-steroidal mineralocorticoid receptor antagonist (MRA) proteinuria eGFR decline real-world evidence
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/0886022X.2026.2644719
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!